Why post approval evidence is redefining the future of patient care 

By Sandra Silvestri, for Ipsen.com 

In today’s rapidly evolving treatment landscape the approval of a medicine is no longer the finish line; it’s just the beginning. Real world evidence (RWE), post-hoc analyses and structured Phase IV studies all offer new opportunities for scientific learning. At Ipsen, we’re committed to pursuing the unanswered questions, generating robust evidence that goes beyond medicine development, which provides broader long-term evidence-based perspectives for the communities we serve. 

The expanding role of RWE 

Clinical trials answer essential scientific questions, but by design, they can never fully capture the reality of people’s everyday lives—the diversity of experiences, the complexity of conditions, and the unpredictability of care journeys. 

RWE helps bridge that gap. It reflects what really matters to people: how well a medicine works over time, how tolerable it is day-to-day, and how it fits into the realities of living with a condition. By investing in robust RWE, we are deepening our understanding of patients’ needs, capturing the genuine impact of our medicines and ensuring they continue to deliver meaningful benefits for the people who rely on them. 

Post-hoc analyses and Phase IV trials: deepening insight where it matters most 

Post hoc analyses and Phase IV studies, conducted after a medicine is approved, play an equally important role. Directed by the diversity of patients and the often-varied care pathways, we explore assumptions to generate insights in the context of real-world challenges. How do our medicines impact patients with certain comorbidities or receiving other medications? What other markers may be clinically relevant to investigate? How has the treatment landscape and in turn, treatment guidelines evolved? By taking a focused approach, we’re designing analyses to answer the most pressing topics for clinicians and patients, enriching understanding and supporting more individualized care. 

A future defined by continuous learning 

Real world insights combined with the depth of Phase IV trials and post-hoc analyses, offer a powerful, multidimensional understanding of a medicine’s impact. For Ipsen, data generation post approval is not an add on, it is a commitment. A commitment to truly understand the impact of our medicines, not just for the many but for the unique individuals who deserve answers.  

The future of patient care will depend on this continuous learning mindset. Approval is a milestone worth celebrating, but it is not the end. Every real-world insight, every long-term outcome, every post-approval analysis brings us closer to optimizing care for the people who need it most. Our goal is clear: to ensure that scientific progress does not stop at approval but accelerates through it so that every patient receives not only an innovative medicine, but one that evolves with evidence, precision and purpose.